

Pharma & API: 2026 Budget Changes

Sector / Sub-Vertical	Specific Item	Pre-2026 Position	Post-2026 Budget	Reference
Bulk Natural Honey — cough-syrup/formulation input (H.S. 0409.00.90)	Direct Benefit — Customs Duty (SD)	CONFLICTING: 10% SD proposed vs. 25% SD per gazette	0% SD for bulk honey imported by manufacturing industries	SRO 151-Ain/2026/06/Customs, Table-6
Pharma & API	Anti-Cancer Drug Raw Materials	Standard import duties and VAT applied to formulation raw materials.	Import duty and VAT reduced to 0% on 9 new raw materials for anti-cancer drug production.	SRO-153-Ain-2026/08/Customs
Cleanroom sandwich panels — pharma manufacturing facility build-out	Direct Benefit — Customs Duty (Capital Machinery)	Not stated	Flat 1% Customs Duty	SRO 152-Ain/2026/07/Customs
Pharma & API	API Domestic Protection (51 Raw Materials)	Concessional or moderate import tariffs on basic raw materials.	Import duty increased to 100% on 51 raw materials for Active Pharmaceutical Ingredient (API) production to enforce domestic self-sufficiency.	SRO 152-Ain/2026/07/Customs
Mortuary storage / cold-chain systems — public-health infrastructure	Direct Benefit — Customs Duty	25% Customs Duty	1% Customs Duty	Bangladesh Customs Tariff
Pharma & API	Export Sustaining Raw Materials	Standard tariff lines applied to basic formulation inputs.	Import duty reduced to 0% on 17 basic raw materials for the pharmaceutical industry to support export competitiveness.	SRO-154-Ain-2026/09/Customs
Pharma & API	Biological Safety Cabinets	25% Import Duty.	Import duty reduced from 25% to 1%, integrating them into capital equipment concessional benefits.	Bangladesh Customs Tariff & SRO-150-Ain-2026/05/Customs